Theriva Corp (TOVX) - Market Cap to Net Income Ratio

Corporate emblem and logo of Synthetic Biologics (TOVX)

The price chart for Theriva Biologics, Inc. (TOVX) illustrates the price action of an asset whose operating model relies on external contractors for the development of viral vectors and clinical tests. The current metric stands at -0.60. Theriva Biologics, Inc. (TOVX) is developing microbiome protection and anti-tumor therapies. Key growth drivers will include the results of the VCN-01 study, the efficacy of combination therapy, and a potential sale of the business to a major investor.

TOVX therivabio.com: Price to Earnings Ratio in the range 04/28/2023 - 11/18/2026

Analytical breakdowns for Theriva Biologics, Inc.

- market price and analyst price targets:
Comprehensive company analysis:TOVX Synthetic Biologics
Manufactured product of Theriva Biologics, Inc.

The analyst evaluates the issuer's credit quality through the lens of market expectations. The absence of commercial products at Theriva Biologics, Inc. (TOVX) confirms its current stage of investment-driven oncology development. A P/E valuation reflects the cost of a single unit of net profit by dividing the share price by earnings. The trend of this indicator reveals the balance between speculative demand and actual capital efficiency. Sharp fluctuations in the line signal the asset's high sensitivity to regulatory risks.

Competing companies